MedTrace Logo

Antiangiogenic Peptide Vaccine Therapy in Treating Patient With Hepatocellular Carcinoma

NCT01266707 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2010-12-24

No results posted yet for this study

Summary

The purpose of this study is to assess toxicities of angiogenic peptide vaccine therapy in treating HLA-A\*2402 restricted patients with advanced hepatocellular carcinoma.

Conditions

Interventions

BIOLOGICAL

antiangiogenic paptide vaccine

for drugs include administration time frame

Sponsors & Collaborators

  • Human Genome Center, Institute of Medical Science, University of Tokyo

    collaborator OTHER

  • Fukushima Medical University

    lead OTHER

Principal Investigators

  • Mitsukazu Gotoh, PhD & MD · Fukushima Medical University, Department of Regeneration Surgery

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-03-31
Primary Completion
2012-03-31
Completion
2013-03-31

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01266707 on ClinicalTrials.gov